Recursion Pharmaceuticals (Recursion Pharmaceuticals) EBIT per Share : $-1.59 (TTM As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Recursion Pharmaceuticals EBIT per Share?

Recursion Pharmaceuticals's EBIT per Share for the three months ended in Dec. 2023 was $-0.44. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.59.

During the past 3 years, the average EBIT per Share Growth Rate was -30.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Recursion Pharmaceuticals's EBIT per Share or its related term are showing as below:

RXRX' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -36.1 Med: -33.45 Max: -30.8
Current: -30.8

During the past 5 years, the highest 3-Year average EBIT per Share Growth Rate of Recursion Pharmaceuticals was -30.80% per year. The lowest was -36.10% per year. And the median was -33.45% per year.

RXRX's 3-Year EBIT Growth Rate is ranked worse than
81.46% of 1305 companies
in the Biotechnology industry
Industry Median: 3.2 vs RXRX: -30.80

Recursion Pharmaceuticals's EBIT for the three months ended in Dec. 2023 was $-97.03 Mil.

Recursion Pharmaceuticals EBIT per Share Historical Data

The historical data trend for Recursion Pharmaceuticals's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Recursion Pharmaceuticals EBIT per Share Chart

Recursion Pharmaceuticals Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

-0.55

-0.76

-1.46

-1.36

-1.60

Recursion Pharmaceuticals Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EBIT per Share	Get a 7-Day Free Trial												-0.31	-0.34	-0.38	-0.43	-0.44

Recursion Pharmaceuticals EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Recursion Pharmaceuticals's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-332.031	/	207.854
=	-1.60

Recursion Pharmaceuticals's EBIT per Share for the quarter that ended in Dec. 2023 is calculated as

	EBIT per Share		(Q: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-97.032	/	222.143
=	-0.44

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.59

Recursion Pharmaceuticals (NAS:RXRX) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Recursion Pharmaceuticals EBIT per Share Related Terms

Thank you for viewing the detailed overview of Recursion Pharmaceuticals's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Recursion Pharmaceuticals (Recursion Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Recursion Pharmaceuticals Inc (NAS:RXRX) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

41 S Rio Grande Street, Salt Lake City,, UT, USA, 84101

Website

https://www.recursion.com

Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.

Executives

Michael Secora	officer: Chief Financial Officer	C/O RECURSION PHARMACEUTICALS, 41 S. RIO GRANDE STREET, SALT LAKE CITY UT 84101
Shafique Virani	officer: Chief Corp. Dev. Officer	C/O RECURSION PHARMACEUTICALS, 41 S. RIO GRANDE STREET, SALT LAKE CITY UT 84101
Dean Y Li	director	2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Blake Borgeson	director	C/O RECURSION PHARMACEUTICALS, 41 S. RIO GRANDE STREET, SALT LAKE CITY UT 84101
Christopher Gibson	director, 10 percent owner, officer: Chief Executive Officer	C/O RECURSION PHARMACEUTICALS, 41 S. RIO GRANDE STREET, SALT LAKE CITY UT 84101
Tina Marriott Larson	officer: President and COO	C/O RECURSION PHARMACEUTICALS, 41 S. RIO GRANDE STREET, SALT LAKE CITY UT 84101
Zavain Dar	director	C/O LUX CAPITAL MANAGEMENT, LLC, 1600 EL CAMINO REAL - SUITE 290, MENLO PARK CA 94025
Terry-ann Burrell	director	C/O BEAM THERAPEUTICS INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
David J Mauro	officer: Chief Medical Officer	36 TERRELL DRIVE, WASHINGTON CROSS PA 18977
Mubadala Investment Co Pjsc	10 percent owner	P.O. BOX 45005, ABU DHABI C0 00000
Peter Hebert	other: Former 10% Owner	C/O LUX VENTURES, 295 MADISON AVE, 24TH FLOOR, NEW YORK NY 10017
Lux Ventures Iv, L.p.	other: Former 10% Owner	295 MADISON AVENUE, 24TH FLOOR, NEW YORK NY 10017
Lux Venture Partners Iv, Llc	other: Former 10% Owner	920 BROADWAY, 11TH FLOOR, NEW YORK NY 10010
Lux Co-invest Partners, Llc	other: Former 10% Owner	C/O LUX CAPITAL, 920 BROADWAY, 11TH FLOOR, NEW YORK NY 10010
Lux Co-invest Opportunities, L.p.	other: Former 10% Owner	C/O LUX CAPITAL MANAGEMENT, 920 BROADWAY, 11TH FLOOR, NEW YORK NY 10010